Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | CD38 | P28907 | 2/20 | 0.44 |
| ▸ | BTK | Q06187 | 3/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21138491 | 1.00 | JAK2 (0.49) | JAK2JAK1CD38BTKKAT2B | |
| SCHEMBL30808262 | 0.84 | HPGDS (0.47) | JAK2JAK1HPGDSTP53ADORA1 | |
| SCHEMBL21138338 | 0.84 | HPGDS (0.47) | JAK2JAK1HPGDSTP53ADORA1 | |
| SCHEMBL11617161 | 0.82 | HPGDS (0.50) | JAK2JAK1HPGDSTP53ADORA1 | |
| SCHEMBL767164 | 0.80 | HPGDS (0.42) | IRAK4HPGDSTP53EGFR | |
| SCHEMBL21138216 | 0.75 | MAPK8 (0.44) | BTKMAPK8MAPK9HPGDSTP53 | |
| SCHEMBL21138485 | 0.74 | CD38 (0.40) | CD38BTKIRAK4HPGDSEGFR | |
| SCHEMBL21138334 | 0.73 | MAPK8 (0.40) | MAPK8HPGDSTP53EGFR | |
| SCHEMBL21138333 | 0.73 | MAPK8 (0.40) | MAPK8HPGDSTP53EGFR | |
| SCHEMBL21138209 | 0.72 | HPGDS (0.37) | JAK2JAK1CD38BTKIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | disclosed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | PDE7B, PDE3A, PDE7A | JAK2 886/4885JAK1 947/4885CD38 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.